All In Biotech

Drug Trial Radar · NCT04712097

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

478

Actual

Start

Oct 27, 2021

Primary completion

Jun 3, 2026

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

Conditions

  • Relapsed or Refractory Follicular Lymphoma

Interventions

  • MosunetuzumabDrug

    Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12

  • LenalidomideDrug

    Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)

  • RituximabDrug

    Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11

  • TociluzumabDrug

    Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) according to 2014 Lugano Response CriteriaTime frame: From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8.5 years)

Locations

111 sites in 15 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Winship Cancer Institute

    Atlanta, Georgia

  • Fort Wayne Medical Oncology and Hematology, Inc

    Fort Wayne, Indiana

  • Investigative Clinical Research of Indiana, LLC

    Noblesville, Indiana

  • Johns Hopkins Uni

    Baltimore, Maryland

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Cancer & Hematology Center of West Michigan

    Grand Rapids, Michigan

  • Washington University

    St Louis, Missouri

  • NYU Long Island Hospital

    Mineola, New York

  • NYU Langone Ambulatory Care Center

    New York, New York

  • Montefiore Medical Center - Montefiore Medical Park

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest Univ Health Svcs

    Winston-Salem, North Carolina

  • Baylor University Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Princess Alexandra Hospital Woolloongabba

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Geelong Hospital

    Geelong, Victoria, Australia

  • Ictrials Pesquisa e Desenvolvimento

    Curitiba, Paraná, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Mae de Deus

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Alemao Oswaldo Cruz

    São Paulo, São Paulo, Brazil

  • Peking University First Hospital

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • Cancer Center, Sun Yat-sen University of Medical Sciences

    Guangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • The 1st Affiliated Hospital of Nanchang Unversity

    Nanchang, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Zhejiang Cancer Hospital

    Zhejiang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.